• Urologic oncology · May 2018

    Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer.

    • Tarik Benidir, Karen Hersey, Antonio Finelli, Rob Hamilton, Anthony M Joshua, Girish Kulkarni, Alexandre Zlotta, and Neil Fleshner.
    • Uro-Oncology Research Unit, Department of Surgery, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address: tbenidir@qmed.ca.
    • Urol. Oncol. 2018 May 1; 36 (5): 240.e13-240.e20.

    AbstractSeveral new compounds are now available for castration resistant prostate cancer (CRPC). Individual costs range between $40,000 and $93,000 with mean survival extensions from 2.4 to 4.8 months. Currently, it remains unclear how patients with prostate cancer (PCa) value the effect of these therapies in the setting of CRPC.Crown Copyright © 2018. Published by Elsevier Inc. All rights reserved.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…